CD274 and neoplasm: Similarly, outside of England, patients with relapsed or refractory CUP with high PD-L1 expression and no alternative treatment options are eligible for ICIs [10], whilst favourable CUPs with tumours analogous to a primary site with known benefit from immunotherapy, such as NSCLC, urothelial, and head and neck cancers, can also be considered for ICIs [10, 32].